Article
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
PloS one - 1 Jan 2018
Coté Damien, Eustace Alex, Toomey Sinead, Cremona Mattia, Milewska Malgorzata, Furney Simon, Carr Aoife, Fay Joanna, Kay Elaine, Kennedy Susan, Crown John, Hennessy Bryan, Madden Stephen
Abstract excerpt
Breast cancer is the leading cause of cancer related deaths in women worldwide and is classified into subtypes based on the cancer's receptor status. Of these subtypes, those expressing the human epidermal growth factor receptor 2 (HER2) receptor were traditionally associated with poor prognosis. Several advances have been made in the treatment of HER2-positive breast cancer, yet issues of resistance and poor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.